Defence Therapeutics IncCanadian Securities Exchange:DTCView on Grey Market
- LAST PRICE0.6200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6000/ 2
- Ask / Lots0.6500/ 4
- Open / Previous Close--- / 0.6200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Yesterday
Oct 30, 2024
Defence Therapeutics Completes 1st Tranche of Financing, from 6:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
6:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Defence Therapeutics Inc | 28.2M | -2.1x | --- |
Sona Nanotech Inc | 29.0M | -8.4x | --- |
Thiogenesis Therapeutics Corp | 27.3M | -5.5x | --- |
Resverlogix Corp | 15.3M | -1.1x | --- |
BioMark Diagnostics Inc | 21.4M | -12.3x | --- |
Helix BioPharma Corp | 37.3M | -3.6x | --- |
Company Information
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.
Contact Information
- Headquarters
- 1680- 200 Burrard StreetVANCOUVER, BC, Canada V6C 3L6
- Phone
- 514-947-2272
- Fax
- ---
Executives
- Interim Chief Executive Officer
- Kwin Grauer
- Chief Financial Officer, Director
- P. Meagher
- Vice President - Research & Development, Director
- Moutih Rafei
- Director
- Sebastien Plouffe
- Independent Director
- Raimar Lobenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 45.5M |
Defence Therapeutics Inc does not pay a dividend. | |
Beta | 1.44 |
EPS | $-0.30 |
Book Value | $-0.08 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
